Template provided by FormBlends — formblends.com | Free GLP-1 Patient Resources
Instructions: Fill in all blue underlined fields with your specific information. Give this letter to your prescribing physician to sign and submit to your insurance company. Fields marked with brackets [like this] need your specific details.
Date:
[Insurance Company Name]
[Insurance Company Address]
[City, State, ZIP]
Re: Prior Authorization Request
Patient Name: [Patient Full Name]
Date of Birth: [DOB]
Member ID: [Member ID Number]
Group Number: [Group Number]
Medication Requested: [Semaglutide / Tirzepatide / Other]
Requested Dose: [Starting dose and titration schedule]
To Whom It May Concern:
I am writing to request prior authorization for [medication name] for my patient, [patient name], for the treatment of obesity/overweight with associated comorbidities. I believe this medication is medically necessary based on the clinical evidence presented below.
Patient Clinical Profile
[Patient name] is a [age]-year-old [male/female] with a current Body Mass Index (BMI) of [BMI] kg/m2 (height: [height], weight: [weight]). The patient meets the FDA-approved indication for this medication, which requires a BMI of 30 kg/m2 or greater, or a BMI of 27 kg/m2 or greater with at least one weight-related comorbidity.
Relevant Comorbidities
The patient has the following weight-related comorbidities (check all that apply):
- ☐ Type 2 Diabetes Mellitus (A1C: [value]%)
- ☐ Hypertension (BP: [value])
- ☐ Dyslipidemia (LDL: [value], Triglycerides: [value])
- ☐ Obstructive Sleep Apnea
- ☐ Non-Alcoholic Fatty Liver Disease (NAFLD)
- ☐ Osteoarthritis of weight-bearing joints
- ☐ Cardiovascular disease or elevated cardiovascular risk
- ☐ Other: [specify]
Prior Weight Loss Interventions
The patient has attempted the following weight loss interventions without achieving or maintaining clinically significant weight loss:
- ☐ Structured diet and exercise program for [duration]
- ☐ Medically supervised weight management program
- ☐ Previous weight loss medication: [name, duration, reason for discontinuation]
- ☐ Behavioral counseling / cognitive behavioral therapy
- ☐ Other: [specify]
Clinical Evidence Supporting This Request
The efficacy and safety of this medication is well-established in large-scale randomized controlled trials:
- STEP Trials (Semaglutide): The STEP program demonstrated mean weight loss of 14.9% to 17.4% of body weight at 68 weeks, with significant improvements in cardiometabolic risk factors. (Wilding et al., NEJM 2021)
- SURMOUNT Trials (Tirzepatide): The SURMOUNT-1 trial showed mean weight loss of 15.0% to 22.5% of body weight at 72 weeks depending on dose. (Jastreboff et al., NEJM 2022)
- SELECT Trial: Semaglutide 2.4mg demonstrated a 20% reduction in major adverse cardiovascular events in patients with overweight/obesity and established cardiovascular disease. (Lincoff et al., NEJM 2023)
Treatment Plan
I plan to prescribe [medication name] at an initial dose of [dose], titrating to [target dose] per the FDA-approved titration schedule. The patient will be monitored with regular office visits every [interval] and periodic blood work to assess metabolic markers. Concurrent lifestyle modifications including a reduced-calorie diet and increased physical activity will continue.
Based on the patient's clinical profile, failed prior interventions, and the strong evidence base supporting this medication class, I believe this treatment is medically necessary. I respectfully request approval of this prior authorization.
Please contact my office at [phone number] if additional information is needed to process this request. Thank you for your prompt attention to this matter.
Sincerely,
[Provider Name, Credentials]
[Practice Name]
[NPI Number]
[Address]
[Phone / Fax]
This letter template is provided for informational purposes only by FormBlends (formblends.com). It does not constitute medical advice, legal advice, or a guarantee of insurance coverage. Individual insurance policies vary. Work with your healthcare provider to customize this letter for your specific clinical situation.